Nasdaq:US$19.15 (-0.41) | HKEX:HK$30.70 (-0.15) | AIM:£3.10 (+0)
搜索
新闻中心及演示文稿

中国香港、上海和美国新泽西州：2022年4月27日，星期三：和黄医药（中国）有限公司（简称“和黄医药”或“本公司”）（纳斯达克/伦敦证交所：HCM；香港交易所：13）今天宣布，于 2022 年 4 月 27 日举行之股东周年大会（“股东周年大会”）上提呈之普通决议案及特别决议案均获正式通过。决议案之投票表决结果如下:

普通决议案 票数 (%)* 股东通过
赞成 反对 弃权 #
1. 考虑及接纳截至2021年12月31日止年度之经审核财务报表、董事会报告及独立核数师报告。

686,224,906

(99.9996%)

2,960

( 0.0004%)

 7,697,445 是
2(A). 重选杜志强先生为董事。

635,955,913

(92.4452%)

51,971,563

(7.5548%)

 5,997,835 是
2(B). 重选苏慰国博士为董事。

686,123,331

(99.7377%)

1,804,145

(0.2623%)

 5,997,835 是
2(C). 重选郑泽锋先生为董事。

685,947,446

(99.7122%)

1,980,030

(0.2878%)

 5,997,835 是
2(D). 重选艾乐德博士为董事。

684,647,400

(99.5232%)

3,280,076

(0.4768%)

 5,997,835 是
2(E). 重选施熙德女士为董事。

681,250,085

(99.0294%)

6,677,146

(0.9706%)

 5,998,080 是
2(F). 重选卡博乐先生为董事。

686,252,741

(99.7566%)

1,674,735

(0.2434%)

 5,997,835 是
2(G). 重选费凯宁医生为董事。

687,778,031

(99.9783%)

149,445

(0.0217%)

 5,997,835 是
2(H). 重选席纪伦先生为董事。

674,126,615

(98.1141%)

12,957,617

(1.8859%)

 6,841,079 是
2(I). 重选莫树锦教授为董事。

670,413,452

(97.4558%)

17,501,649

(2.5442%)

 6,010,210 是
3. 就香港财务报告及美国财务报告目的，分别委聘罗兵咸永道会计师事务所及普华永道中天会计师事务所（特殊普通合伙）为本公司核数师，并授权董事厘定核数师薪酬。

685,514,922

(98.7906%)

8,392,264

(1.2094%)

 18,125 是
特别决议案
4. 授予本公司董事一般性授权以发行额外股份。^

683,701,055

(99.3864%)

4,221,351

(0.6136%)

 6,002,905 是
普通决议案
5(1). 授予本公司董事一般性授权以购回本公司股份。^

687,914,356

(99.9989%)

7,770

( 0.0011%)

 6,003,185 是
5(2). 更新长期奖励计划项下的计划授权限额。^

601,082,095

(91.7604%)

53,973,751

(8.2396%)

 38,869,465 是

* 所有百分比皆计至小数点后 4 个位。
#    “弃权”票于法律上不属投票，故于计算决议案的“赞成”及“反对”票比例时不计算在内。
^ 第 4 及 5 项决议案的全文载于股东周年大会通告内。

 

本公司所有董事（即杜志强先生、苏慰国博士、郑泽锋先生、艾乐德博士、施熙德女士、卡博乐先生、费凯宁医生、席纪伦先生及莫树锦教授）均亲身或以电子设施方式出席了股东周年大会。

附注：

  1. 赋予股份持有人出席股东周年大会权利，并于会上就全部决议案有表决权的股份总数：864,530,850 股。
  2. 赋予股份持有人出席股东周年大会权利，惟根据香港联合交易所有限公司证券上市规则（“上市规则”）第 13.40 条所载须放弃表决赞成决议案的股份总数：零股。
  3. 上市规则规定须于股东周年大会上放弃表决权的股份持有人所持股份总数：零股。
  4. 股东周年大会投票表决监票员为 Computershare Investor Services (Jersey) Limited（本公司的股份登记总处）。

 

关于和黄医药

和黄医药（纳斯达克/伦敦证交所：HCM；香港交易所：13）是一家处于商业化阶段的创新型生物医药公司，致力于发现、全球开发和商业化治疗癌症和免疫性疾病的靶向药物和免疫疗法。集团旗下公司共有超过 4,600 名员工，其中核心的肿瘤/免疫业务拥有约 1,500 人的团队。自成立以来，和黄医药已将自主发现的 12 个候选癌症药物推进到在全球开展临床研究，其中首三个创新肿瘤药物现已于中国获批上市。欲了解更多详情，请访问： www.hutch-med.com或关注我们的 LinkedIn专页。

Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 21, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on April 20, 2020 to the following persons discharging managerial responsibilities were vested on April 20, 2022:-

Award Holder   Number of American depositary shares (“ADS”)
Mr Simon To (Executive Director) 2,3971
Dr Dan Eldar (Non-executive Director (“NED”)) 2,397
Ms Edith Shih (NED) 2,3972
Mr Paul Carter (Independent Non-executive Director (“INED”)) 2,0373
Dr Karen Ferrante (INED) 2,397
Mr Graeme Jack (INED) 2,397
Professor Tony Mok (INED) 2,397
Notes:
      1. Similar to the arrangement for his Director’s fees, these ADSs were not received by Mr Simon To, but were received by or for the account of his employer, Hutchison Whampoa (China) Limited.
      2. Similar to the arrangement for her Director’s fees, these ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.
      3. Mr Paul Carter elected, on acceptance of the grant of his awards, to have 15% of his LTIP awards (amounting to US$7,500 with respect to his awards which vested on April 20, 2022) held on his behalf by the trustee administering the LTIP pending vesting in the form of cash, to settle his tax liabilities in respect of his awards.

 

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

 

(a) Dr Dan Eldar

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Dan Eldar
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,397 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

(b) Mr Paul Carter

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Paul Carter
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,037 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

(c) Dr Karen Ferrante

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Karen Ferrante
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,397 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

(d) Mr Graeme Jack

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Graeme Jack
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,397 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

(e) Professor Tony Mok

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Professor Tony Mok
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,397 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

 

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786

Media Enquiries
Americas – Brad Miles,
Solebury Trout		 +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe – Ben Atwell / Alex Shaw,
FTI Consulting		 +44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com
Asia – Zhou Yi,
Brunswick		 +852 9783 6894 (Mobile)
HUTCHMED@brunswickgroup.com

Nominated Advisor
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited		 +44 (20) 7886 2500